713 results on '"Creutzberg, Carien L"'
Search Results
52. Supplementary Table 7 from A Transcriptionally Distinct CXCL13+CD103+CD8+ T-cell Population Is Associated with B-cell Recruitment and Neoantigen Load in Human Cancer
53. Supplementary Tables 1-6, 8 from A Transcriptionally Distinct CXCL13+CD103+CD8+ T-cell Population Is Associated with B-cell Recruitment and Neoantigen Load in Human Cancer
54. Supplementary Figures from A Transcriptionally Distinct CXCL13+CD103+CD8+ T-cell Population Is Associated with B-cell Recruitment and Neoantigen Load in Human Cancer
55. Supplementary Data from Prognostic Integrated Image-Based Immune and Molecular Profiling in Early-Stage Endometrial Cancer
56. Supplementary figure 6 from POLE Proofreading Mutations Elicit an Antitumor Immune Response in Endometrial Cancer
57. Table S3 from Adjuvant Treatment for POLE Proofreading Domain–Mutant Cancers: Sensitivity to Radiotherapy, Chemotherapy, and Nucleoside Analogues
58. Supplementary figure 1 from POLE Proofreading Mutations Elicit an Antitumor Immune Response in Endometrial Cancer
59. Supplementary Table S5 from Improved Risk Assessment by Integrating Molecular and Clinicopathological Factors in Early-stage Endometrial Cancer—Combined Analysis of the PORTEC Cohorts
60. Figure S1 from Adjuvant Treatment for POLE Proofreading Domain–Mutant Cancers: Sensitivity to Radiotherapy, Chemotherapy, and Nucleoside Analogues
61. Supplementary figure 4 from POLE Proofreading Mutations Elicit an Antitumor Immune Response in Endometrial Cancer
62. Supplementary table 2 from POLE Proofreading Mutations Elicit an Antitumor Immune Response in Endometrial Cancer
63. Figure S4 from Amplification of 1q32.1 Refines the Molecular Classification of Endometrial Carcinoma
64. Supplementary figure 5 from POLE Proofreading Mutations Elicit an Antitumor Immune Response in Endometrial Cancer
65. Supplementary Methods from Adjuvant Treatment for POLE Proofreading Domain–Mutant Cancers: Sensitivity to Radiotherapy, Chemotherapy, and Nucleoside Analogues
66. Supplementary figure 2 from POLE Proofreading Mutations Elicit an Antitumor Immune Response in Endometrial Cancer
67. Supplementary figure 3 from POLE Proofreading Mutations Elicit an Antitumor Immune Response in Endometrial Cancer
68. Supplementary table 1 from POLE Proofreading Mutations Elicit an Antitumor Immune Response in Endometrial Cancer
69. International validation of two EORTC questionnaires for assessment of health‐related quality of life for patients with high‐grade non‐Hodgkin lymphoma (QLQ‐NHL‐HG29) and low‐grade non‐Hodgkin lymphoma (QLQ‐NHL‐LG20)
70. QPOLE:A Quick, Simple, and Cheap Alternative for POLE Sequencing in Endometrial Cancer by Multiplex Genotyping Quantitative Polymerase Chain Reaction
71. Clinical Behavior and Molecular Landscape of Stage I p53-Abnormal Low-Grade Endometrioid Endometrial Carcinomas
72. Time Trends in the Treatment and Survival of 5036 Uveal Melanoma Patients in The Netherlands over a 30-Year Period
73. Clinical Behavior and Molecular Landscape of Stage I p53-Abnormal Low-Grade Endometrioid Endometrial Carcinomas
74. Interpretable deep learning model to predict the molecular classification of endometrial cancer from haematoxylin and eosin-stained whole-slide images: a combined analysis of the PORTEC randomised trials and clinical cohorts
75. Radiation therapy combined with hyperthermia versus cisplatin for locally advanced cervical cancer: Results of the randomized RADCHOC trial
76. Toxicity and quality of life after adjuvant chemoradiotherapy versus radiotherapy alone for women with high-risk endometrial cancer (PORTEC-3): an open-label, multicentre, randomised, phase 3 trial
77. Prognostic significance of L1CAM expression and its association with mutant p53 expression in high-risk endometrial cancer
78. Groin surgery and risk of recurrence in lymph node positive patients with vulvar squamous cell carcinoma
79. Long-Term Impact of Endometrial Cancer Diagnosis and Treatment on Health-Related Quality of Life and Cancer Survivorship: Results From the Randomized PORTEC-2 Trial
80. Variability in clinical target volume delineation for intensity modulated radiation therapy in 3 challenging cervix cancer scenarios
81. Selecting Adjuvant Treatment for Endometrial Carcinoma Using Molecular Risk Factors
82. Molecular Classification Predicts Response to Radiotherapy in the Randomized PORTEC-1 and PORTEC-2 Trials for Early-Stage Endometrioid Endometrial Cancer.
83. International validation of two EORTC questionnaires for assessment of health‐related quality of life for patients with high‐grade non‐Hodgkin lymphoma (QLQ‐NHL‐HG29) and low‐grade non‐Hodgkin lymphoma (QLQ‐NHL‐LG20)
84. An easy, fast, and accurate way for implementing the standards of care for the management of patients with endometrial carcinoma into daily clinical practice: the ESGO mobile app.
85. Cancer of the corpus uteri
86. Refining prognosis and identifying targetable pathways for high-risk endometrial cancer; a TransPORTEC initiative
87. Qualitative Accounts of Patients' Determinants of Vaginal Dilator Use after Pelvic Radiotherapy
88. Nomograms for Prediction of Outcome With or Without Adjuvant Radiation Therapy for Patients With Endometrial Cancer: A Pooled Analysis of PORTEC-1 and PORTEC-2 Trials
89. 2022-RA-825-ESGO The impact of age on prognosis in women with endometrial cancer: a pooled analysis of the PORTEC-1, -2 and -3 randomised trials
90. 2022-RA-450-ESGO Benefit of adjuvant radiotherapy depends on molecular class of early-stage endometrial cancer
91. 2022-RA-683-ESGO The ENSURE trial for women with early-stage endometrial cancer: A randomized controlled trial comparing the effect of a reduced versus usual follow-up schedule on patient satisfaction, health care use, and disease perceptions
92. 2022-RA-809-ESGO Underlying causes and prognosis of mismatch repair deficiency in endometrial cancer other thanMLH1promoter hypermethylation
93. Impact of Cardiovascular Counseling and Screening in Hodgkin Lymphoma Survivors
94. Second primary cancers in survivors of cervical cancer in the Netherlands: Implications for prevention and surveillance
95. High concordance of molecular tumor alterations between pre-operative curettage and hysterectomy specimens in patients with endometrial carcinoma
96. ESGO Survey on Current Practice in the Management of Cervical Cancer
97. Blinded histopathological characterisation of POLE exonuclease domain‐mutant endometrial cancers: sheep in wolfʼs clothing
98. ENdometrial cancer SURvivors’ follow-up carE (ENSURE): Less is more? Evaluating patient satisfaction and cost-effectiveness of a reduced follow-up schedule: study protocol of a randomized controlled trial
99. Loss of ARID1A expression and its relationship with PI3K-Akt pathway alterations, TP53 and microsatellite instability in endometrial cancer
100. Adaptive objective configuration in bi-objective evolutionary optimization for cervical cancer brachytherapy treatment planning
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.